<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/82321AD2-CD2E-456C-9395-59CF155A3EC8"><gtr:id>82321AD2-CD2E-456C-9395-59CF155A3EC8</gtr:id><gtr:name>Sanofi</gtr:name><gtr:address><gtr:line1>174 avenue de France</gtr:line1><gtr:line4>Paris cedex 13</gtr:line4><gtr:postCode>75635</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B"><gtr:id>46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B</gtr:id><gtr:name>Bristol-Myers Squibb</gtr:name><gtr:address><gtr:line1>Bristol-Myers Squibb</gtr:line1><gtr:line2>311 Pennington Rocky Hill Road</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5A51966A-5E02-4F70-A0D3-68077A2C4C03"><gtr:id>5A51966A-5E02-4F70-A0D3-68077A2C4C03</gtr:id><gtr:name>Merck &amp; Co. Inc. (MSD)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/8C84A3AD-28FF-49F8-A939-0A7EB5A43E05"><gtr:id>8C84A3AD-28FF-49F8-A939-0A7EB5A43E05</gtr:id><gtr:name>European Association for the Study of Diabetes (EASD)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/620DB27D-4014-4278-AAD1-11105CC6BDEA"><gtr:id>620DB27D-4014-4278-AAD1-11105CC6BDEA</gtr:id><gtr:name>Novo Nordisk</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Clinical and Experimental Medicine</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/82321AD2-CD2E-456C-9395-59CF155A3EC8"><gtr:id>82321AD2-CD2E-456C-9395-59CF155A3EC8</gtr:id><gtr:name>Sanofi</gtr:name><gtr:address><gtr:line1>174 avenue de France</gtr:line1><gtr:line4>Paris cedex 13</gtr:line4><gtr:postCode>75635</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B"><gtr:id>46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B</gtr:id><gtr:name>Bristol-Myers Squibb</gtr:name><gtr:address><gtr:line1>Bristol-Myers Squibb</gtr:line1><gtr:line2>311 Pennington Rocky Hill Road</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5A51966A-5E02-4F70-A0D3-68077A2C4C03"><gtr:id>5A51966A-5E02-4F70-A0D3-68077A2C4C03</gtr:id><gtr:name>Merck &amp; Co. Inc. (MSD)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/8C84A3AD-28FF-49F8-A939-0A7EB5A43E05"><gtr:id>8C84A3AD-28FF-49F8-A939-0A7EB5A43E05</gtr:id><gtr:name>European Association for the Study of Diabetes (EASD)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/620DB27D-4014-4278-AAD1-11105CC6BDEA"><gtr:id>620DB27D-4014-4278-AAD1-11105CC6BDEA</gtr:id><gtr:name>Novo Nordisk</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8E005E45-0D5A-4376-9C54-BE675ADCB2F2"><gtr:id>8E005E45-0D5A-4376-9C54-BE675ADCB2F2</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Brian</gtr:otherNames><gtr:surname>Dunger</gtr:surname><gtr:orcidId>0000-0002-2566-9304</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/47CADA54-7D87-4AE5-AE9E-345555D9F1BF"><gtr:id>47CADA54-7D87-4AE5-AE9E-345555D9F1BF</gtr:id><gtr:firstName>Jerry</gtr:firstName><gtr:surname>Wales</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/55AE47AD-25E6-4F1B-98D2-7A341F63EAE0"><gtr:id>55AE47AD-25E6-4F1B-98D2-7A341F63EAE0</gtr:id><gtr:firstName>Timothy</gtr:firstName><gtr:surname>Barrett</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C3308329-3894-43F7-A39A-11733F67A8AF"><gtr:id>C3308329-3894-43F7-A39A-11733F67A8AF</gtr:id><gtr:firstName>Julian</gtr:firstName><gtr:surname>HamiltonShield</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0800661"><gtr:id>3F497291-CF57-4815-AFBA-B6C6A816A5C5</gtr:id><gtr:title>Type 2 diabetes in childhood: building a platform to support novel intervention strategies</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800661</gtr:grantReference><gtr:abstractText>The rise in childhood obesity has led to children developing obesity related type 2 diabetes, something that was never seen in the UK 20 years ago. We know that these children will get serious cardiovascular disease in adulthood; but we do not know what are the best treatments to prevent or delay the onset to these diseases. This proposal is to establish a UK national cohort of children with type 2 diabetes, carefully characterised, so that they can be involed in clinical trials of treatments to improve their outcomes.</gtr:abstractText><gtr:technicalSummary>Obesity related Type 2 diabetes now occurs in children; we described the first UK cases in 2000 (Ehtisham S et al 2000) and shown that there are approximately 70 new cases a year under 17 completed years in the UK (Haines L et al 2007). There is a minimal evidence base for treatment of childhood type 2 diabetes, and children are not included in the NICE guidelines on the management of type 2 diabetes in the UK. We propose to establish a national cohort of children with type 2 diabetes. The purposes are to develop a tightly characterized cohort for intervention with clinical trials that will develop the evidence base for treatment; and to determine the natural history of type 2 diabetes in a UK population diagnosed in childhood.</gtr:technicalSummary><gtr:fund><gtr:end>2014-04-25</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-04-27</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>721167</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Merck &amp; Co. Inc. (MSD)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Commercial - Merck Sharpe Dohme</gtr:description><gtr:id>BB43E07A-57D2-424F-B687-845941ABEF64</gtr:id><gtr:impact>Recruitment commenced, first patients in the UK, from the MRC patient cohort</gtr:impact><gtr:partnerContribution>Our partners (n=60) are investigating their recruits to the MRC patient cohorts to identify other eligible children.</gtr:partnerContribution><gtr:piContribution>The title of the clinical trial is: A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Pediatric Patients with Type 2 Diabetes Mellitus from MRC cohort to phase III study. 

Our team has recruited the first UK patients to this study from the MRC patient cohort</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sanofi</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Sanofi-Aventis</gtr:department><gtr:description>Commercial - Sanofi Aventis</gtr:description><gtr:id>FD445B86-DF1B-48F1-A75B-A8B74C317874</gtr:id><gtr:impact>Study on hold until further eligible patients identified</gtr:impact><gtr:partnerContribution>recruitment of patients</gtr:partnerContribution><gtr:piContribution>Recruitment from MRC patient cohort to phase III study</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Association for the Study of Diabetes (EASD)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>Academic: EASD</gtr:description><gtr:id>E9B32BEE-91B6-418F-B775-F5E5ACE4CE4D</gtr:id><gtr:impact>Currently in write-up</gtr:impact><gtr:partnerContribution>None</gtr:partnerContribution><gtr:piContribution>Co-applicant on grant, but not CI. Recruited patients from MRC patient cohort</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novo Nordisk</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>Liraglutide Phase 2 trial</gtr:description><gtr:id>433B1B4A-9D4E-414C-9107-079A5D65D2E2</gtr:id><gtr:impact>National Research Ethics has been obtained. Patients being approached in December 2010, study to commence January 2011.</gtr:impact><gtr:piContribution>Chief UK Investigator for the UK sites. Input into the protocol. Recruitment of patients from the MRC Patient Cohorts study of type 2 diabetes in children.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bristol-Myers Squibb</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Commercial: clinical study Bristol Myers Squibb</gtr:description><gtr:id>58041512-57F5-4456-9D1A-9BC1BA037EB8</gtr:id><gtr:impact>Recruitment ongoing</gtr:impact><gtr:partnerContribution>Ditto</gtr:partnerContribution><gtr:piContribution>Recruitment from MRC patient cohort to Phase III study</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novo Nordisk</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>Commercial - Novo Nordisk</gtr:description><gtr:id>D279BD8B-146B-48E9-BC37-4B8D078BF1CB</gtr:id><gtr:impact>Screening and Recruitment is ongoing</gtr:impact><gtr:partnerContribution>Our 60 NHS partners who have been recruiting to the MRC patient cohort, have been screening their local patients for children eligible to this study.</gtr:partnerContribution><gtr:piContribution>Study title: Effect of Liraglutide in combination with metformin versus metformin mono therapy on glycaemic control in children and adolescents with type 2 diabetes; a 14 week double-blind, randomised, parallel group, placebo controlled multi-venter study followed by a 38 week open label extension. Screening of patients from MRC patient cohort for recruitment to this phase III study</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Update on childhood type 2 diabetes</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9D160EF1-3E6B-4E1B-BAF8-CD3DA32B619B</gtr:id><gtr:impact>This was a presentation at the Diabetes UK annual professional and patient conference, attended by many members affected by diabetes

There was a lot of interest generated in the development of type 2 diabetes in young people</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to South Asian Health Foundation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>45BE75F4-BB86-470F-B564-AA4B83E81172</gtr:id><gtr:impact>This alerted delegates to the fact that type 2 diabetes disproportionately affects children from South Asian communities and black communities

Greater awareness of the issues</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Parent support group meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9D3A1921-4D03-4DA2-8E26-3E9031E4CFE8</gtr:id><gtr:impact>I presented this study to our parent group at which there were 30 families with diabetes. I had interest from those families with children affected by type 2 diabetes.

Families were relieved to know that there was research going on in their child's disease area.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>European Foundation for the Study of Diabetes (EFSD)</gtr:department><gtr:description>Research grant scheme/European Foundation for the Study of Diabetes</gtr:description><gtr:end>2012-08-02</gtr:end><gtr:fundingOrg>European Association for the Study of Diabetes (EASD)</gtr:fundingOrg><gtr:id>B522F34D-1F43-412C-8C2D-7F2EDD6C4163</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>320000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR TRC Rare Diseases Patient Cohorts round 1</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:id>1ADFBF77-7D96-4EA5-886B-87188A7132AA</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Input into international guideline on childhood type 2 diabetes</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>ISPAD Guidelines on management of childhood diabetes</gtr:guidelineTitle><gtr:id>4B532EAC-F7F0-4A0F-9BC3-EC62D10D9C9E</gtr:id><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influence on revision to NICE guidelines on management of diabetes in children</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>NICE Guideline on management of childhood diabetes</gtr:guidelineTitle><gtr:id>1A75CA83-BB40-41CA-8A4E-DEDBCB298D39</gtr:id><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/130B3615-437C-457C-A00F-71040536E78A"><gtr:id>130B3615-437C-457C-A00F-71040536E78A</gtr:id><gtr:title>Expanding Treatment Options for Youth With Type 2 Diabetes: Current Problems and Proposed Solutions: A White Paper From the NICHD Diabetes Working Group.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/89977768d1b6d75e4a6025838b7e9dda"><gtr:id>89977768d1b6d75e4a6025838b7e9dda</gtr:id><gtr:otherNames>Tamborlane WV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/36A3D976-71D8-4DA3-AE47-5EDFE4AFBFE9"><gtr:id>36A3D976-71D8-4DA3-AE47-5EDFE4AFBFE9</gtr:id><gtr:title>Type 2 diabetes in the child and adolescent</gtr:title><gtr:parentPublicationTitle>Pediatric Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/69916310ed9ae004c41632422d0a161d"><gtr:id>69916310ed9ae004c41632422d0a161d</gtr:id><gtr:otherNames>Zeitler P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0C970D29-6D72-40F9-8D4B-FB099784C0F3"><gtr:id>0C970D29-6D72-40F9-8D4B-FB099784C0F3</gtr:id><gtr:title>Adolescents' views and experiences of treatments for type 2 diabetes: a qualitative study</gtr:title><gtr:parentPublicationTitle>Diabetic Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0c80be75756212afac3ac175db6adaa3"><gtr:id>0c80be75756212afac3ac175db6adaa3</gtr:id><gtr:otherNames>Turner K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/53FE2B7C-C7E2-46D7-8177-155F4AC8999B"><gtr:id>53FE2B7C-C7E2-46D7-8177-155F4AC8999B</gtr:id><gtr:title>Joining forces: a call for greater collaboration to study new medicines in children and adolescents with type 2 diabetes.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/96c0446fbc11eb17076425118041043a"><gtr:id>96c0446fbc11eb17076425118041043a</gtr:id><gtr:otherNames>Karres J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/42A0464E-FB7B-4F1B-9C65-4CE26D9CD0CE"><gtr:id>42A0464E-FB7B-4F1B-9C65-4CE26D9CD0CE</gtr:id><gtr:title>Home urine C-peptide creatinine ratio (UCPCR) testing can identify type 2 and MODY in pediatric diabetes.</gtr:title><gtr:parentPublicationTitle>Pediatric diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c1ee90e5fd8944aabc08d46f91deacf1"><gtr:id>c1ee90e5fd8944aabc08d46f91deacf1</gtr:id><gtr:otherNames>Besser RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1399-543X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800661</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>208C592B-C1B7-4E87-A19A-04E8D9458E50</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>6.9  Resources and infrastructure (evaluation of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>